ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 028,28
1,13%
Dow Jones
41 488,19
1,65%
DAX
22 986,82
2,01%
Brent Oil
70,285
0,00%
Bitcoin
84 287,01
0,39%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Syros Pharmaceuticals Inc (SYRS)

  7. Syros Pharmaceuticals Inc (SYRS) Actualités

SYRS

Syros Pharmaceuticals (SYRS)

Syros Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:SYRS
DateHeureSourceTitreSymboleSociété
12/03/202505h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SYRSSyros Pharmaceuticals Inc
10/03/202521h31Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:SYRSSyros Pharmaceuticals Inc
10/03/202521h13Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:SYRSSyros Pharmaceuticals Inc
10/03/202521h05Edgar (US Regulatory)Form 25 - Notification of the removal from listing and registration of matured, redeemed or retired securitiesNASDAQ:SYRSSyros Pharmaceuticals Inc
04/03/202522h31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SYRSSyros Pharmaceuticals Inc
28/02/202522h05Business WireSyros Announces Voluntary Delisting from Nasdaq and SEC DeregistrationNASDAQ:SYRSSyros Pharmaceuticals Inc
14/02/202522h09Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:SYRSSyros Pharmaceuticals Inc
16/01/202522h49Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SYRSSyros Pharmaceuticals Inc
20/11/202423h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SYRSSyros Pharmaceuticals Inc
14/11/202423h28Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:SYRSSyros Pharmaceuticals Inc
12/11/202422h30Business WireSyros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene OverexpressionNASDAQ:SYRSSyros Pharmaceuticals Inc
31/10/202412h30Business WireSyros Reports Third Quarter 2024 Financial Results and Provides a Business UpdateNASDAQ:SYRSSyros Pharmaceuticals Inc
31/10/202411h49Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SYRSSyros Pharmaceuticals Inc
24/10/202413h08Business WireSyros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024NASDAQ:SYRSSyros Pharmaceuticals Inc
27/08/202413h00Business WireSyros Pharmaceuticals to Present at Upcoming Medical and Investor ConferencesNASDAQ:SYRSSyros Pharmaceuticals Inc
12/08/202422h15Business WireSyros Provides Update on SELECT-AML-1 Phase 2 Clinical TrialNASDAQ:SYRSSyros Pharmaceuticals Inc
31/07/202413h44Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SYRSSyros Pharmaceuticals Inc
31/07/202413h30Business WireSyros Reports Second Quarter 2024 Financial Results and Provides a Business UpdateNASDAQ:SYRSSyros Pharmaceuticals Inc
24/07/202413h00Business WireSyros to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024NASDAQ:SYRSSyros Pharmaceuticals Inc
13/06/202413h00Business WireSyros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene OverexpressionNASDAQ:SYRSSyros Pharmaceuticals Inc
14/05/202413h30Business WireSyros Reports First Quarter 2024 Financial Results and Provides a Corporate UpdateNASDAQ:SYRSSyros Pharmaceuticals Inc
07/05/202415h00Business WireSyros to Participate in Upcoming Investor ConferencesNASDAQ:SYRSSyros Pharmaceuticals Inc
07/05/202413h00Business WireSyros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024NASDAQ:SYRSSyros Pharmaceuticals Inc
09/04/202413h00Business WireSyros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpressionNASDAQ:SYRSSyros Pharmaceuticals Inc
02/04/202422h30Business WireSyros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SYRSSyros Pharmaceuticals Inc
27/03/202412h30Business WireSyros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate UpdateNASDAQ:SYRSSyros Pharmaceuticals Inc
27/03/202411h57IH Market NewsU.S. Stock Index Futures Point to a Rebound, Oil See Declines in Early TradingNASDAQ:SYRSSyros Pharmaceuticals Inc
25/03/202412h00Business WireSyros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 TrialNASDAQ:SYRSSyros Pharmaceuticals Inc
20/03/202412h00Business WireSyros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024NASDAQ:SYRSSyros Pharmaceuticals Inc
27/02/202413h00Business WireSyros to Participate in TD Cowen 44th Annual Health Care ConferenceNASDAQ:SYRSSyros Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:SYRS

Dernières Valeurs Consultées

AMEX
FRI
First Trust S&P REIT
USOTC
AUKUD
AMS OSARM (PK)
AMEX
FXR
First Trust Industrials ...
USOTC
BADEF
Hercules Metals (QB)
AMEX
UNG
United States Natural Gas
BIT
GOLD1L
SG Issuer
LSE
0M26
Xoma
AMEX
EWJ
IShares MSCI Japan
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
BBY
Best Buy
AMEX
VPU
Vanguard Utilities ETF
TG
A2G809
Deutsche Apotheker and A...
USOTC
JAYAF
PT Jaya Konstruksi Mangg... (CE)
AMEX
GXC
SPDR S&P China
TG
TA1
Telekom Austria
AMEX
XLY
Consumer Discretionary S...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces